About the 15th Annual Biotech in Europe ForumThe forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. We expect over 600+ delegates and 100+ presenting companies.
The 15th Annual is held for the second time in Basel to be close to the largest biopharma hub in Europe and the Congress Center provides meeting space capable of handling several thousand one- to- one meetings as well as significant exhibition space. The Programme will feature twelve plenary panels/workshops covering BD & Licensing in the main therapeutic areas. The Meeting will provide a number of networking opportunities via our online 1-2-1 meeting system which allows you to pre-book meetings with all the attendees. We expect more than 1500 meetings to take place throughout the 2 days. Additionally there will be social events on the evenings of the conference, with a reception at The Grand Hotel Les Trois Rois hosted by The Canton of Basel-Stadt on 29th of September. Forum Panels included:
|
Financial/Advisory/
Investors Attending: AbbVie Biotech Ventures Abingworth LLP ACXIT Lifesciences GmbH Advent Life Sciences Aescap Venture Aravis SA Arcus Ventures BB Biotech Ventures Bellevue Asset Management Belsize Asset Management Bergmann zur Hausen & Cie. BioGeneration Ventures BioMedPartners AG Breslin AG BZ Bank Aktiengesellschaft Capricorn Venture Partners Catalysis Capital Partners CBT Advisors CD-Venture GmbH Cederberg GmbH Cukierman & Co. Life Sciences Deloitte LLP Deutsche Bank AG Edison Group Edmond de Rothschild Investment Partners Eminent Venture Capital Corporation / TaiAn Technologies Ernst & Young Excellentia Global Partners Forbion Capital Partners FreeMind Group Gilde Healthcare Global Life Science Ventures HBM Partners AG Hestia Investments High-Tech Gruenderfonds Management GmbH Ikarian Capital Imperial College Innovations Inbio Ventures Industrifonden Inserm Transfert Inserm Transfert Initiative IPF Partners IPSA JPI Funds JSB Partners LP KarinJorga Life Science Consulting GmbH LSP Lundbeckfond Ventures MedImmune Ventures, Inc. Mediqventures MedTech Innovation Partners AG MedVenture Partners GmbH Ventures Mercadyne Investments, LLC Mirabaud Securities LLP MPM Capital MS Ventures MSD Research Laboratories Muse Capital LLP NetScientific UK Nextech Invest Ltd. Norgine Ventures Novartis Venture Fund Novo A/S NRW Bank Omega Funds Oxford Finance, LLC PARfinance Peel Hunt LLP Percipient Capital PharmaVentures Ltd. Remaco AG RMI Partners Rockport Venture Partners Royal Bank of Canada (Suisse) S.R.One, Limited Salus Partners Seroba Kernel Life Sciences Seventure Partners Silicon Valley Bank Sirius Healthcare Partners SIX Swiss Exchange Sixth Element Capital Societe Generale Stifel Financial Corp. Sunstone Capital A/S Syncona Partners Thuja Capital B.V. Torreya Partners (Europe) LLC TVM Capital UBS AG Ventac Partners GmbH VI Partners AG Visium Asset UK LLP Vogel BioC Vontobel Bank Warwick Ventures WBB Capital WBB Securities, LLC Wellington Partners XOventure GmbH Yorkville Advisors, LLC Ysios Capital Partners ZukunftsAgentur Brandenburg GmbH Zukunftsfonds Heilbronn GmbH & Co KG Zürcher Kantonalbank |
Sachs Associates Switzerland AG
|
Sachs Associates Ltd.
|
T: +44 203 463 4890
E: SachsTeam@SachsForum.com
© COPYRIGHT 2023. ALL RIGHTS RESERVED.